[go: up one dir, main page]

EA201001853A1 - Фармацевтическая комбинация - Google Patents

Фармацевтическая комбинация

Info

Publication number
EA201001853A1
EA201001853A1 EA201001853A EA201001853A EA201001853A1 EA 201001853 A1 EA201001853 A1 EA 201001853A1 EA 201001853 A EA201001853 A EA 201001853A EA 201001853 A EA201001853 A EA 201001853A EA 201001853 A1 EA201001853 A1 EA 201001853A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical combination
radiation therapy
describes
application
diseases
Prior art date
Application number
EA201001853A
Other languages
English (en)
Other versions
EA020046B1 (ru
Inventor
Мартин Фридрих Штефаник
Франк Хильберг
Рольф Кайзер
Дейвид Шапиро
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40912046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201001853(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201001853A1 publication Critical patent/EA201001853A1/ru
Publication of EA020046B1 publication Critical patent/EA020046B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)

Abstract

В заявке описана фармацевтическая комбинация, которую можно использовать для лечения заболеваний, которые включают пролиферацию клеток, миграцию или апоптоз миеломных клеток, ангиогенез или фиброз. В заявке описан также способ лечения указанных заболеваний, который заключается в том, что эффективные количества специфических активных соединений вводят одновременно, раздельно или последовательно, и/или способ совместного лечения с лучевой терапией в соотношении, которое обеспечивает аддитивное и синергетическое действие, а также комбинированное применение указанных специфических соединений и/или лучевой терапии для получения соответствующих фармацевтических комбинированных препаратов.
EA201001853A 2008-06-06 2009-06-04 Фармацевтическая комбинация EA020046B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08157749 2008-06-06
US7888208P 2008-07-08 2008-07-08
PCT/EP2009/056891 WO2009147218A1 (en) 2008-06-06 2009-06-04 Pharmaceutical combination

Publications (2)

Publication Number Publication Date
EA201001853A1 true EA201001853A1 (ru) 2011-06-30
EA020046B1 EA020046B1 (ru) 2014-08-29

Family

ID=40912046

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001853A EA020046B1 (ru) 2008-06-06 2009-06-04 Фармацевтическая комбинация

Country Status (34)

Country Link
US (5) US20110178099A1 (ru)
EP (2) EP2985025B1 (ru)
JP (2) JP5993573B2 (ru)
KR (1) KR101760657B1 (ru)
CN (1) CN102056609B (ru)
AR (1) AR072061A1 (ru)
AU (1) AU2009254554B2 (ru)
CA (1) CA2726644C (ru)
CO (1) CO6280488A2 (ru)
CY (2) CY1116877T1 (ru)
DK (2) DK2985025T3 (ru)
EA (1) EA020046B1 (ru)
EC (1) ECSP10010716A (ru)
ES (2) ES2662824T3 (ru)
HK (1) HK1152640A1 (ru)
HR (2) HRP20151186T1 (ru)
HU (2) HUE037291T2 (ru)
IL (1) IL208953B (ru)
LT (1) LT2985025T (ru)
MA (1) MA32384B1 (ru)
ME (1) ME02273B (ru)
MX (1) MX338047B (ru)
MY (1) MY158929A (ru)
NZ (1) NZ588957A (ru)
PE (1) PE20100084A1 (ru)
PL (2) PL2985025T3 (ru)
PT (2) PT2985025T (ru)
RS (2) RS57035B1 (ru)
SI (2) SI2293795T1 (ru)
TW (1) TWI447113B (ru)
UA (1) UA102258C2 (ru)
UY (1) UY31866A (ru)
WO (1) WO2009147218A1 (ru)
ZA (1) ZA201007594B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20110301177A1 (en) 2008-06-06 2011-12-08 Boehringer Ingelheim International Gmbh Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) * 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US10661301B2 (en) * 2015-10-21 2020-05-26 Capsugel Belgium Nv Printing process for oral dosage forms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
WO2005070469A1 (en) * 2004-01-23 2005-08-04 Sarissa, Inc. Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
AU6890800A (en) * 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
UA75054C2 (ru) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Замещенные в положении 6 индолиноны, их получение и их применение как лекарственного средства
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2006023010A1 (en) * 2004-08-18 2006-03-02 Salmedix, Inc. Alanosine formulations and methods of use
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
EP1934226A2 (en) * 2006-08-14 2008-06-25 Sicor, Inc. Highly pure pemetrexed diacid and processes for the preparation thereof

Also Published As

Publication number Publication date
WO2009147218A1 (en) 2009-12-10
MA32384B1 (fr) 2011-06-01
JP2015007143A (ja) 2015-01-15
ME02273B (me) 2016-02-20
LT2985025T (lt) 2018-04-10
DK2293795T3 (en) 2015-10-19
CY1120505T1 (el) 2019-07-10
CA2726644A1 (en) 2009-12-10
PT2985025T (pt) 2018-03-15
JP2011522008A (ja) 2011-07-28
CY1116877T1 (el) 2017-04-05
US20160250218A1 (en) 2016-09-01
HK1152640A1 (en) 2012-03-09
PL2985025T3 (pl) 2018-06-29
MY158929A (en) 2016-11-30
PT2293795E (pt) 2015-11-17
IL208953A0 (en) 2011-01-31
ECSP10010716A (es) 2011-02-28
IL208953B (en) 2018-03-29
RS54293B1 (en) 2016-02-29
SI2293795T1 (sl) 2015-12-31
CN102056609B (zh) 2012-12-05
TWI447113B (zh) 2014-08-01
AU2009254554B2 (en) 2015-08-20
DK2985025T3 (en) 2018-03-19
JP5993573B2 (ja) 2016-09-14
HRP20180602T1 (hr) 2018-05-18
EP2293795B1 (en) 2015-08-12
NZ588957A (en) 2013-03-28
US20110178099A1 (en) 2011-07-21
AR072061A1 (es) 2010-08-04
HUE025821T2 (en) 2016-04-28
EP2985025B1 (en) 2018-01-17
AU2009254554A1 (en) 2009-12-10
CN102056609A (zh) 2011-05-11
US20130237549A1 (en) 2013-09-12
UA102258C2 (en) 2013-06-25
ES2662824T3 (es) 2018-04-09
CA2726644C (en) 2018-02-06
HUE037291T2 (hu) 2018-08-28
PE20100084A1 (es) 2010-02-05
KR101760657B1 (ko) 2017-07-24
EA020046B1 (ru) 2014-08-29
TW201002690A (en) 2010-01-16
KR20110025172A (ko) 2011-03-09
ES2552238T3 (es) 2015-11-26
SI2985025T1 (en) 2018-04-30
HRP20151186T1 (hr) 2015-12-04
UY31866A (es) 2010-01-29
RS57035B1 (sr) 2018-05-31
MX2010012937A (es) 2011-02-25
ZA201007594B (en) 2011-07-27
EP2293795A1 (en) 2011-03-16
MX338047B (es) 2016-03-31
US20150174126A1 (en) 2015-06-25
CO6280488A2 (es) 2011-05-20
PL2293795T3 (pl) 2016-01-29
EP2985025A1 (en) 2016-02-17
US20180243308A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
EA201001853A1 (ru) Фармацевтическая комбинация
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
MX372883B (es) Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA200971053A1 (ru) Способы лечения кожных язв
EA201300558A1 (ru) Соединения и способы для купирования боли
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
AR086051A1 (es) Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit
PH12020551427A1 (en) Epinephrine spray formulations
EP3818991A3 (en) Compositions and methods for treating diseases
EA201190344A1 (ru) Составы для лечения боли в глубоких тканях
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
EA201100626A1 (ru) Лечение рака с помощью ионизирующего облучения и иммуноцитокинов
EA200702523A1 (ru) Применение эритропоэтина в низкой дозировке для стимуляции эндотелиальных клеток-предшественников, а также для регенерации органов и замедления прогрессирования повреждений конечных органов
EA201390217A1 (ru) Способы лечения алкогольной интоксикации, расстройств, связанных с употреблением алкоголя, и злоупотребления алкоголем, которые включают введение дигидромирицетина
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
EA202192964A1 (ru) Комбинированная терапия
EA202190294A1 (ru) Комбинированная терапия для лечения рака
TN2010000556A1 (en) Pharmaceutical combination
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
EA202190291A1 (ru) Комбинированная терапия для лечения рака

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG MD TJ TM

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AZ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU